Grace Therapeutics, Inc. GRCE 深 沪
已收盘 07-31 16:00:00 美东时间
2.08
+0.010
+0.48%
华盛通- 最 高2.1702
- 今 开2.10
- 成交量 17.75万股
- 最 低 2.03
- 昨 收 2.07
- 总市值 3385.00万
- 52周最高 5.18
- 市盈率 静 --
- 换手率 1.09%
- 52周最低 1.79
- 委 比 20.54%
- 总股本 1627.40万
- 历史最高 2016.00
- 量 比 0.37
- 振 幅 6.77%
- 历史最低 1.75
- 每 手 1
- 风险率 0.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Grace Therapeutics Receives FDA Meeting Minutes From Type A Meeting; FDA Confirms No Clinical Safety Or Efficacy Deficiencies
FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA Resubmission PRINCETON, N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ...
07-28 19:06
Grace Therapeutics Q4 EPS $(0.06) Beats $(0.15) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.15) by 60 percent. This is a 160 percent decrease over earnings of $0.10 per share from the same period last year.
06-18 21:43
美股大行评级 | 潜在涨幅33%！大小摩等9家大行上调英特尔目标价；Popular、都福集团、联合太平洋、联合租赁等获多家大行上调评级
今日重点评级关注：瑞银：维持SS&C科技"买入"评级，目标价从112美元升至115美元；Piper Sandler：维持儒博实业"超配"评级，目标价从530美元升至540美元
04-27 14:04
Grace Therapeutics, Inc. Receives FDA Complete Response Letter For GTx-104, No New Clinical Data Required; Intends To Resubmit Application Following Resolution Of Cited Items
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA Does not Request Additional Clinical DataCompany Intends to Resubmit
04-24 01:17
Grace Therapeutics Announces Acceptance Of Abstract Highlighting Results From STRIVE-ON Phase 3 Safety Trial For Presentation At 2026 American Academy of Neurology Meeting, April 18-22
The STRIVE-ON Trial results will be presented as a poster on April 21, 2026. Details are as follows:Session: S21: Neurocritical CareDate: April 21,
04-14 20:12
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Lunai Bioworks (NASDAQ:LNAI) stock moved upwards by 47.2% to $0.41 dur...
04-08 01:05
Grace Therapeutics Q3 EPS $(0.14) Beats $(0.28) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.28) by 50 percent. This is a 61.11 percent increase over losses of $(0.36) per share from
02-12 21:11
Grace Therapeutics Q2 EPS $(0.06) Beats $(0.18) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.18) by 67.57 percent. This is a 80 percent increase over losses of $(0.30) per share from
2025-11-13 21:12
Grace Therapeutics Secures $4M Through Warrant Exercise
Grace Therapeutics ( ($GRCE) ) has shared an update. On October 23, 2025, Grace...
2025-10-23 20:28
Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review
Grace Therapeutics, Inc. has secured $4 million in additional funding through the exercise of common warrants issued in a 2023 private placement to support its lead drug candidate, GTx-104, an injectable nimodipine formulation for treating aneurysmal subarachnoid hemorrhage (aSAH). The U.S. FDA has set a PDUFA target date of April 23, 2026, for reviewing the Company's NDA for GTx-104. aSAH is a rare and severe type of stroke caused by brain aneur...
2025-10-23 12:00
